NCT05630989 A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy
| NCT ID | NCT05630989 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mandana Kamgar, MD |
| Condition | Pancreatic Ductal Adenocarcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 80 participants |
| Start Date | 2023-02-07 |
| Primary Completion | 2027-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 80 participants in total. It began in 2023-02-07 with a primary completion date of 2027-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an observational precision oncology study designed to collect and analyze data that allows us to characterize the safety and efficacy of several different mitogen-activated protein kinase kinase inhibitor (MEKi) -based treatment strategies and the feasibility of administering MEKi combination therapies to patients with KRAS G12R mutated advanced pancreatic ductal adenocarcinoma (PDAC).
Eligibility Criteria
Inclusion Criteria: 1. Age ≥18 years. 2. Diagnosis of advanced pancreatic ductal adenocarcinoma as determined by the treating physician or tumor board. 3. Tumor must have KRAS G12R mutation, as determined by a next generation sequencing (NGS) panel or circulating tumor DNA panel of choice of the treating physician. 4. Ability to understand a written informed consent document and the willingness to sign it. Exclusion Criteria: 1. Age \<18 years. 2. Primary cancer diagnosis other than advanced pancreatic ductal adenocarcinoma 3. Tumor does not have a KRAS G12R mutation.
Contact & Investigator
Mandana Kamgar, MD, MPH
PRINCIPAL INVESTIGATOR
Medical College of Wisconsin
Frequently Asked Questions
Who can join the NCT05630989 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pancreatic Ductal Adenocarcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05630989 currently recruiting?
Yes, NCT05630989 is actively recruiting participants. Contact the research team at mkamgar@mcw.edu for enrollment information.
Where is the NCT05630989 trial being conducted?
This trial is being conducted at Milwaukee, United States.
Who is sponsoring the NCT05630989 clinical trial?
NCT05630989 is sponsored by Mandana Kamgar, MD. The principal investigator is Mandana Kamgar, MD, MPH at Medical College of Wisconsin. The trial plans to enroll 80 participants.